Injection Device

Patent metadata

Field	Value
Publication number	US-2016129200-A1
Application number	US-201414897381-A
Country	US
Kind code	A1
Filing date	Jun 11, 2014
Priority date	Jun 11, 2013
Publication date	May 12, 2016
Grant date	—

Abstract

An injection device comprises an actuator adapted when actuated to cause commencement of an injection sequence; a locking mechanism adapted to be moved between a locked position in which the locking mechanism prevents the actuator from being actuated, and an unlocked position in which the actuator can be actuated to cause commencement of the injection sequence. The locking mechanism comprises a contact portion which in the locked position of the locking mechanism projects against the actuator. The contact portion comprises a curved surface.

First claim

1 . An injection device comprising:
an actuator adapted when actuated to cause commencement of an injection sequence; a locking mechanism adapted to be moved between a locked position in which the locking mechanism prevents the actuator from being actuated, and an unlocked position in which the actuator can be actuated to cause commencement of the injection sequence, wherein the locking mechanism comprises a contact portion which in the locked position of the locking mechanism projects against the actuator, wherein the contact portion comprises a curved surface.

2 . The injection device of claim 1 , wherein the actuator comprises an engagement surface.

3 . The injection device of claim 2 , wherein the engagement surface is a planar surface.

4 . The injection device of claim 2 or claim 3 , wherein the locking mechanism is adapted such that the contact portion is in contact with the engagement surface of the actuator when the locking mechanism is in its locked position.

5 . The injection device of any of the claims 2 to 4 , wherein the locking mechanism is adapted such that the curved surface of the contact portion is in contact with the engagement surface over only a sub-part of the contact portion when the locking mechanism is not in its unlocked position.

6 . The injection device of any of the claims 2 to 5 , wherein the locking mechanism is adapted such that the contact portion is not in contact with the engagement surface of the actuator when the locking mechanism is in its unlocked position.

7 . The injection device of any of the claims 2 to 6 , wherein the locking mechanism is moveable between its locked position and its unlocked position such that the contact portion moves from a position in which it contacts the engagement surface of the actuator to a position in which is no longer contacts the engagement surface of the actuator.

8 . The injection device of claim 7 , wherein the locking mechanism slides between its locked position and unlocked position along a first axis A.

9 . The injection device of any one of claims 2 to 8 , wherein the contact portion comprises a protrusion which extends from the locking mechanism.

10 . The injection device of claim 9 , wherein the protrusion extends along a second axis B.

11 . The injection device of any one of claims 2 to 10 , wherein the engagement surface is a surface on a first portion which extends from the actuator.

12 . The injection device of claim 11 , wherein the first portion extends along third axis C.

13 . The injection device of claim 12 when dependent on claim 9 , wherein the second axis B and third axis C intersect each other with an intersection angle of between 45 and 90 degrees, 60 and 90 degrees, 80 and 90 degrees, or 90 degrees.

14 . The injection device of claim 13 when dependent on claim 7 , wherein the first axis A and third axis C are parallel to each other.

15 . The injection device of claim 14 , wherein the second axis B intersects both the first axis A and the third axis C.

16 . The injection device of any one of the preceding claims, wherein the actuator moves between a first position in which commencement of the injection sequence is prevented, and a second position in which commencement of the injection sequence occurs.

17 . The injection device of claim 16 , further comprising a drive mechanism, wherein the actuator comprises a locking surface which inhibits the drive mechanism when the actuator is in its first position and which does not inhibit the drive mechanism when the drive mechanism is in its second position.

18 . The injection device of claim 17 , wherein the actuator rotates between its first and second positions about a pivot.

19 . The injection device of claim 18 when dependent on claim 10 , wherein the axis of the pivot and the second axis B substantially intersect each other with an intersection angle of between 45 and 90 degrees, 60 and 90 degrees, 80 and 90 degrees, or 90 degrees.

20 . The injection device of any one of the preceding claims when dependent on claim 17 , further comprising a syringe which is moveable by the drive mechanism on commencement of the injection sequence from a position in which the syringe is wholly contained within a body of the injection device to a position in which a needle of the syringe extends from the body of the injection device via an opening, wherein the drive mechanism is adapted to expel contents of the syringe via the needle when the syringe is in its extended position.

21 . An injection device according to any of the preceding claims
containing a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity.

22 . A substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines,
for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of said substance to a human subject using an injection device according to any one of claims 1 to 20 .

23 . An injection device for use in the treatment or prevention rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity,
by delivery of a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids,

Assignees

• Cilag Gmbh Int

Inventors

• Jennings Douglas Ivan
• Bitar Ahmad

Classifications

• A61M5/3204 Primary

  Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices · CPC title

• A61M2005/208

  Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin · CPC title

• A61M2005/206

  With automatic needle insertion · CPC title

• A61M2005/2073

  preventing premature release, e.g. by making use of a safety lock · CPC title

• A61M5/2033 Primary

  Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287) · CPC title